OIPE JC68
MAY 18 2004
PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-03)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known	
Application Number	10/681,858
Filing Date	October 7, 2003
First Named Inventor	Piomelli, Daniele
Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	02307E-127510US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No.[1]	Document Number Number Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BP	1.	6,096,784 A	08-01-2000	Lerner et al.	
BP	2.	6,271,015 B1	08-07-2001	Gilula et al.	
BP	3.	6,326,156 B1	12-04-2001	Civelli et al.	
BP	4.	6,359,010 B1	03-19-2002	Geracioti, Jr. et al.	
BP	5.	6,562,846 B2	05-13-2003	Sit et al.	
BP	6.	2002/0187542 A1	12-12-2002	Gilula et al.	
BP	7.	2002/0188009 A1	12-12-2002	Sit et al.	
BP	8.	2003/0149082 A1	08-07-2003	Makriyannis et al.	
BP	9.	2003/0195226 A1	10-16-2003	Sit et al.	
BP	10.	USSN 60/336,289	N/A (Filed 10-31-2001)	Piomelli et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document Country Code[3]	Number[4]	Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
BP	11.	WO	98/24396	A2	06-11-1998	Neurosci. Res. Found.		☐
BP	12.	WO	03/065989	A2	08-14-2003	Bristol-Myers		☐
								☐

Examiner Signature		Date Considered	12-12-2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] **Applicant's** unique citation designation number **(optional)**. [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known	
Application Number	10/681,858
Filing Date	October 7, 2003
First Named Inventor	Piomelli, Daniele
Art Unit	1614
Examiner Name	To Be Assigned
Attorney Docket Number	02307E-127510US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
BD	13.	BARNETT-NORRIS, J. et al., "Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor" J. Med. Chem. 451:3649-3659 (2002).	
BD	14.	BELTRAMO, M. et al., "Inhibition of anandamide hydrolysis in rat brain tissue by (E)-6-(bromomethylene) tetrahydro-3-(1-naphthalenyl)-2H-pyran-2-one" FEBS Lett. 403:263-267 (1997).	
BD	15.	BISOGNO, T. et al., "Fatty acid amide hydrolase, an enzyme with many bioactive substrates. possible therapeutic implications" Curr. Pharm. Des. 8:533-547 (2002).	
BD	16.	BOGER, D. et al., "Exceptionally potent inhibitors of fatty acid amide hydrolase: The enzyme responsible for degradation of endogenous oleamide and anadamide" Proc. Natl. Acad. Sci. USA 97:5044-5049 (2000).	
BD	17.	BRACEY, M. et al., "Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling" Science 298:1793-1796 (2002).	
BD	18.	CRAVATT, B. et al., "Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase" Proc. Natl. Acad. Sci. USA 98:9371-9376 (2001).	
BD	19.	DE PETROCELLIS, L. et al., "Novel inhibitors of brain, neuronal, and basophilic anandamide amidohydrolase" Biochem. Biophys. Res. Commun. 231:82-88 (1997).	
BD	20.	DEUTSCH, D. et al., "Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor" Biochem. Biophys. Res. Commun. 231:217-221 (1997).	
BD	21.	DINH, T. et al., "Brain monoglyceride lipase participating in endocannabinoid inactivation" Proc. Natl. Acad. Sci. USA 99:10819-10824 (2002).	
BD	22.	KATHURIA, S. et al., "Modulation of anxiety through blockade of anandamide hydrolysis" Nature Medicine 9(1):76-81 (2003).	
BD	23.	KOUTEK, B. et al., "Inhibitors of arachidonoyl ethanolamide hydrolysis" J. Biol. Chem. 269:22937-22940 (1994).	
BD	24.	LOPEZ-RODRIGUEZ, M., et al., "Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects on fatty acid amidohydrolase" J. Med. Chem. 46:1512-1522 (2003).	
BD	25.	PIOMELLI, D. et al., "The endocannabinoid system as a target for therapeutic drugs" Trends Pharmacol. Sci. 21:218-224 (2000).	
BD	26.	QUISTAD, G. et al., "Fatty acid hydrolase inhibition by neurotoxic organophosphorus pesticides" Toxicology and Applied Pharmacology 173:48-55 (2001).	
BD	27.	REGGIO, P. et al., "Conformational requirements for endocannabinoid interaction with the cannabinoid receotirs, the anandamide transporter and fatty acid amidohydrolase" Chem. Phys. Lipids 108:15-35 (2000).	
BD	28.	SMITH, A., "Endocannabinoid System: FAAH better anxiolytics?" Nat. Rev. Drug Discov. 2:92 (2003).	
BD	29.	TARZIA, G. et al., "Design, synthesis, and structure-activity relationships of alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors" J. Med. Chem. 46:2352-2360 (2003).	

Examiner Signature		Date Considered	12-12-2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				*Application Number*	10/681,858
				Filing Date	October 7, 2003
				First Named Inventor	Piomelli, Daniele
				Art Unit	1614
(use as many sheets as necessary)				*Examiner Name*	To Be Assigned
Sheet	3	of	3	*Attorney Docket Number*	02307E-127510US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
BM	30.	WENDELER, M. et al., "Inhibitors of endocannabinoid degradation: potential therapeutics for neurological disorders" Angew. Chem. Int. Ed. 42:2938-2941 (2003).	

60174555 v1

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.

OIPE IAP2
OCT 11 2005
PATENT & TRADEMARK OFFICE

PTO/SB/08A (08-03)

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 2

	Complete if Known
Application Number	10/681,858
Filing Date	October 7, 2003
First Named Inventor	Piomelli, Daniele
Art Unit	1614
Examiner Name	Bernard Dentz
Attorney Docket Number	02307E-127510US

U.S. PATENT DOCUMENTS+

Examiner Initials*	Cite No.[1]	Document Number: Number Kind Code[2] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BD	1	US-3,275,512	09-27-1966	Lemin et al.	
BD	2	US-3,632,631	01-4-1972	Wright et al.	
BD	3	US-3,880,908	04-29-1975	Fields et al.	
BD	4	US-5,112,859	05-12-1992	Commons et al.	
BD	5	US-5,476,944	12-19-1995	Partis et al.	
BD	6	US-6,919,358	04-10-2003	Cheng et al.	
BD	7	US-6,908,939	07-17-2003	Bernardon, et al.	
BD	8	US-6,927,228	02-26-2004	Bernardon, et al.	
BD	9	US-2005/0137238	06-23-2005	Bernardon, et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No.[1]	Foreign Patent Document: Country Code[3]	Number[4]	Kind Code[5] (*if known*)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T[6]
BD	10	WO	02/08185	A1	01-31-2002	F-Hoffmann-La Roche AG		☐
BD	11	WO	02/12210	A1	02-14-2002	Galderma Research & Development		☐
BD	12	WO	03/051841	A2	06-26-2003	Novo Nordisk A/S		Abst.
BD	13	WO	03/051842	A2	06-26-2003	Novo Nordisk A/S		☐
BD	14	EP	1 231 212	A1	08-14-2002	Pfizer Products Inc.		
BD	15	JP	8-92167	A	04-09-1996	Idemitsu Kosan Co.		☐
								Abst.
								☐

Examiner Signature	BD	Date Considered	12-12-2005

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. [1] **Applicant's** unique citation designation number **(optional)**. [2] Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. [3] Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). [4] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [5] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. [6] Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO	Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Application Number	10/681,858
	Filing Date	October 7, 2003
	First Named Inventor	Piomelli, Daniele
	Art Unit	1614
(use as many sheets as necessary)	Examiner Name	Bernard Dentz
Sheet 2 of 2	Attorney Docket Number	02307E-127510US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No.[1]	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T[2]
BD	16	BARNES, J.H. et al., "The preparation and pharmacology of some phenolic carbamates and allophanates." J. Pharmacy Pharmacol., Vol. 13, pp. 39-48, (1961)	
BD	17	BISOGNO, T. et al., "Fatty acid amide hydrolase, an enzyme with many bioactive substrates. Possible therapeutic implications." Curr. Pharmaceut. Des., Vol. 8, 533-47 (2002)	
BD	18	BROWN, L.W. and A.A. Forist, "In vitro and in vivo hydrolysis of salicylanilide N-methylcarbamate and 4-biphenylyl N-methylcarbamate." J. Pharm. Sci., Vol. 61, No., 6, pp. 858-60 (1972)	
BD	19	KOHN, G.K., et al., "Some structural relations of a group of simple alkylphenyl N-methylcarbamates to anticholinestrase activity." J. Agric. Food Chem., Vol. 13, No. 3, pp. 232-5 (1965)	
BD	20	LOPEZ-RODRIGUEZ, M.L. et al., "Design, synthesis, and biological evaluation of new inhibitors of the endocannabinoid uptake: Comparison with effects of fatty acid amidohydrolase." J. Med. Chem., Vol. 46, No. 8, pp. 1512-22 (2003)	
BD	21	QUESNELLE, C.A. et al., "Directed ortho metalation - cross coupling connections. Nickel (0)-catalyzed cross coupling of aryl triflates with organozinc reagents." Synlett, Vol. 5, No. 5, pp. 349-50 (May 1994)	
BD	22	SMITH, A., "FAAH better anxiolytics?" Nature Reviews Drug Discovery Vol. 2, p. 92 (2003)	
BD	23	WOODS, G.F. et al., "M-diarylbenzenes." J. Am. Chem. Soc., Vol. 73, pp 3854-6 (1951)	
BD	24	WOODS, G.F., "Preparation and properties of some polyphenyls." WADC Technical Report, 59-496, pp. 1-170 (1959)	

60599184 v1

Examiner Signature	BD	Date Considered	12-12-2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
[1] Applicant's unique citation designation number (optional). [2] Applicant is to place a check mark here if English language Translation is attached.